|
1
|
Bertuccio P, Chatenoud L, Levi F, Praud D,
Ferlay J, Negri E, Malvezzi M and La Vecchia C: Recent patterns in
gastric cancer: A global overview. Int J Cancer. 125:666–673. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Peleteiro B, Bastos A, Ferro A and Lunet
N: Prevalence of helicobacter pylori infection worldwide: A
systematic review of studies with national coverage. Dig Dis Sci.
59:1698–1709. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hiripi E, Jansen L, Gondos A, Emrich K,
Holleczek B, Katalinic A, Luttmann S, Nennecke A and Brenner H:
Gekid Cancer Survival Working Group: Survival of stomach and
esophagus cancer patients in Germany in the early 21st century.
Acta Oncol. 51:906–914. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hundahl SA, Phillips JL and Menck HR: The
National Cancer Data Base Report on poor survival of U.S. gastric
carcinoma patients treated with gastrectomy: Fifth Edition American
Joint Committee on Cancer staging, proximal disease, and the
‘different disease’ hypothesis. Cancer. 88:921–932. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ushijima T and Sasako M: Focus on gastric
cancer. Cancer Cell. 5:121–125. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Srinivas PR, Kramer BS and Srivastava S:
Trends in biomarker research for cancer detection. Lancet Oncol.
2:698–704. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tan HT, Low J, Lim SG and Chung MC: Serum
autoantibodies as biomarkers for early cancer detection. FEBS J.
276:6880–6904. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Anderson KS and LaBaer J: The sentinel
within: Exploiting the immune system for cancer biomarkers. J
Proteome Res. 4:1123–1133. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Caron M, Choquet-Kastylevsky G and
Joubert-Caron R: Cancer immunomics using autoantibody signatures
for biomarker discovery. Mol Cell Proteomics. 6:1115–1122. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Casiano CA, Mediavilla-Varela M and Tan
EM: Tumor-associated antigen arrays for the serological diagnosis
of cancer. Mol Cell Proteomics. 5:1745–1759. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fernandez Madrid F: Autoantibodies in
breast cancer sera: Candidate biomarkers and reporters of
tumorigenesis. Cancer Lett. 230:187–198. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tan EM: Autoantibodies as reporters
identifying aberrant cellular mechanisms in tumorigenesis. J Clin
Invest. 108:1411–1415. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Davis MA and Hanash S: High-throughput
genomic technology in research and clinical management of breast
cancer. Plasma-based proteomics in early detection and therapy.
Breast Cancer Res. 8:2172006. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Looi KS, Nakayasu ES, Diaz RA, Tan EM,
Almeida IC and Zhang JY: Using proteomic approach to identify
tumor-associated antigens as markers in hepatocellular carcinoma. J
Proteome Res. 7:4004–4012. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang J, Wang K, Zhang J, Liu SS, Dai L
and Zhang JY: Using proteomic approach to identify tumor-associated
proteins as biomarkers in human esophageal squamous cell carcinoma.
J Proteome Res. 10:2863–2872. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peng B, Huang X, Nakayasu ES, Petersen JR,
Qiu S, Almeida IC and Zhang JY: Using immunoproteomics to identify
alpha-enolase as an autoantigen in liver fibrosis. J Proteome Res.
12:1789–1796. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yegin EG and Duman DG: Staging of
esophageal and gastric cancer in 2014. Minerva Med. 105:391–411.
2014.PubMed/NCBI
|
|
19
|
Jung E, Heller M, Sanchez JC and
Hochstrasser DF: Proteomics meets cell biology: The establishment
of subcellular proteomes. Electrophoresis. 21:3369–3377. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dai L, Tsay JC, Li J, Yie TA, Munger JS,
Pass H, Rom WN, Zhang Y, Tan EM and Zhang JY: Autoantibodies
against tumor-associated antigens in the early detection of lung
cancer. Lung Cancer. 99:172–179. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fernandez-Madrid F, Tang N, Alansari H,
Granda JL, Tait L, Amirikia KC, Moroianu M, Wang X and Karvonen RL:
Autoantibodies to Annexin XI-A and other autoantigens in the
diagnosis of breast cancer. Cancer Res. 64:5089–5096. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim JH, Herlyn D, Wong KK, Park DC,
Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS and Mok SC:
Identification of epithelial cell adhesion molecule autoantibody in
patients with ovarian cancer. Clin Cancer Res. 9:4782–4791.
2003.PubMed/NCBI
|
|
23
|
Timms JF and Cramer R: Difference gel
electrophoresis. Proteomics. 8:4886–4897. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brichory FM, Misek DE, Yim AM, Krause MC,
Giordano TJ, Beer DG and Hanash SM: An immune response manifested
by the common occurrence of annexins I and II autoantibodies and
high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci
USA. 98:9824–9829. 2001; View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brichory F, Beer D, Le Naour F, Giordano T
and Hanash S: Proteomics-based identification of protein gene
product 9.5 as a tumor antigen that induces a humoral immune
response in lung cancer. Cancer Res. 61:7908–7912. 2001.PubMed/NCBI
|
|
26
|
Chang JW, Lee SH, Jeong JY, Chae HZ, Kim
YC, Park ZY and Yoo YJ: Peroxiredoxin-I is an autoimmunogenic tumor
antigen in non-small cell lung cancer. FEBS Lett. 579:2873–2877.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hong SH, Misek DE, Wang H, Puravs E,
Giordano TJ, Greenson JK, Brenner DE, Simeone DM, Logsdon CD and
Hanash SM: An autoantibody-mediated immune response to calreticulin
isoforms in pancreatic cancer. Cancer Res. 64:5504–5510. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fujita Y, Nakanishi T, Hiramatsu M,
Mabuchi H, Miyamoto Y, Miyamoto A, Shimizu A and Tanigawa N:
Proteomics-based approach identifying autoantibody against
peroxiredoxin VI as a novel serum marker in esophageal squamous
cell carcinoma. Clin Cancer Res. 12:6415–6420. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Le Naour F, Misek DE, Krause MC, Deneux L,
Giordano TJ, Scholl S and Hanash SM: Proteomics-based
identification of RS/DJ-1 as a novel circulating tumor antigen in
breast cancer. Clin Cancer Res. 7:3328–3335. 2001.PubMed/NCBI
|
|
30
|
Wu JY, Cheng CC, Wang JY, Wu DC, Hsieh JS,
Lee SC and Wang WM: Discovery of tumor markers for gastric cancer
by proteomics. PLoS One. 9:e841582014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
You LR, Chen CM, Yeh TS, Tsai TY, Mai RT,
Lin CH and Lee YH: Hepatitis C virus core protein interacts with
cellular putative RNA helicase. J Virol. 73:2841–2853.
1999.PubMed/NCBI
|
|
32
|
Owsianka AM and Patel AH: Hepatitis C
virus core protein interacts with a human DEAD box protein DDX3.
Virology. 257:330–340. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mamiya N and Worman HJ: Hepatitis C virus
core protein binds to a DEAD box RNA helicase. J Biol Chem.
274:15751–15756. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pugh TJ, Weeraratne SD, Archer TC, Krummel
DA Pomeranz, Auclair D, Bochicchio J, Carneiro MO, Carter SL,
Cibulskis K, Erlich RL, et al: Medulloblastoma exome sequencing
uncovers subtype-specific somatic mutations. Nature. 488:106–110.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Alur M, Nguyen MM, Eggener SE, Jiang F,
Dadras SS, Stern J, Kimm S, Roehl K, Kozlowski J, Pins M, et al:
Suppressive roles of calreticulin in prostate cancer growth and
metastasis. Am J Pathol. 175:882–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chignard N, Shang S, Wang H, Marrero J,
Bréchot C, Hanash S and Beretta L: Cleavage of endoplasmic
reticulum proteins in hepatocellular carcinoma: Detection of
generated fragments in patient sera. Gastroenterology.
130:2010–2022. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gromov P, Gromova I, Bunkenborg J, Cabezon
T, Moreira JM, Timmermans-Wielenga V, Roepstorff P, Rank F and
Celis JE: Up-regulated proteins in the fluid bathing the tumour
cell microenvironment as potential serological markers for early
detection of cancer of the breast. Mol Oncol. 4:65–89. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Iwaki H, Kageyama S, Isono T, Wakabayashi
Y, Okada Y, Yoshimura K, Terai A, Arai Y, Iwamura H, Kawakita M and
Yoshiki T: Diagnostic potential in bladder cancer of a panel of
tumor markers (calreticulin, gamma-synuclein, and
catechol-o-methyltransferase) identified by proteomic analysis.
Cancer Sci. 95:955–961. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hong D, Chen HX, Yu HQ, Wang C, Deng HT,
Lian QQ and Ge RS: Quantitative proteomic analysis of
dexamethasone-induced effects on osteoblast differentiation,
proliferation, and apoptosis in MC3T3-E1 cells using SILAC.
Osteoporos Int. 22:2175–2186. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mizuno H, Honda M, Shirasaki T, Yamashita
T, Yamashita T, Mizukoshi E and Kaneko S: Heterogeneous nuclear
ribonucleoprotein A2/B1 in association with hTERT is a potential
biomarker for hepatocellular carcinoma. Liver Int. 32:1146–1155.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Montagna C, Lyu MS, Hunter K, Lukes L,
Lowther W, Reppert T, Hissong B, Weaver Z and Ried T: The Septin 9
(MSF) gene is amplified and overexpressed in mouse mammary gland
adenocarcinomas and human breast cancer cell lines. Cancer Res.
63:2179–2187. 2003.PubMed/NCBI
|
|
42
|
Bergamaschi A, Christensen BL and
Katzenellenbogen BS: Reversal of endocrine resistance in breast
cancer: Interrelationships among 14-3-3ζ, FOXM1, and a gene
signature associated with mitosis. Breast Cancer Res. 13:R702011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Frasor J, Chang EC, Komm B, Lin CY, Vega
VB, Liu ET, Miller LD, Smeds J, Bergh J and Katzenellenbogen BS:
Gene expression preferentially regulated by tamoxifen in breast
cancer cells and correlations with clinical outcome. Cancer Res.
66:7334–7340. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sun QK, Zhu JY, Wang W, Lv Y, Zhou HC, Yu
JH, Xu GL, Ma JL, Zhong W and Jia WD: Diagnostic and prognostic
significance of peroxiredoxin 1 expression in human hepatocellular
carcinoma. Med Oncol. 31:7862014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Granovsky AE and Rosner MR: Raf kinase
inhibitory protein: A signal transduction modulator and metastasis
suppressor. Cell Res. 18:452–457. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Akaishi J, Onda M, Asaka S, Okamoto J,
Miyamoto S, Nagahama M, Ito K, Kawanami O and Shimizu K:
Growth-suppressive function of phosphatidylethanolamine-binding
protein in anaplastic thyroid cancer. Anticancer Res. 26:4437–4442.
2006.PubMed/NCBI
|
|
47
|
Houben R, Michel B, Vetter-Kauczok CS,
Pföhler C, Laetsch B, Wolter MD, Leonard JH, Trefzer U, Ugurel S,
Schrama D and Becker JC: Absence of classical MAP kinase pathway
signalling in Merkel cell carcinoma. J Invest Dermatol.
126:1135–1142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen Y, Ouyang GL, Yi H, Li MY, Zhang PF,
Li C, Li JL, Liu YF, Chen ZC and Xiao ZQ: Identification of RKIP as
an invasion suppressor protein in nasopharyngeal carcinoma by
proteomic analysis. J Proteome Res. 7:5254–5262. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fu Z, Smith PC, Zhang L, Rubin MA, Dunn
RL, Yao Z and Keller ET: Effects of raf kinase inhibitor protein
expression on suppression of prostate cancer metastasis. J Natl
Cancer Inst. 95:878–889. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chatterjee D, Bai Y, Wang Z, Beach S, Mott
S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, et al:
RKIP sensitizes prostate and breast cancer cells to drug-induced
apoptosis. J Biol Chem. 279:17515–17523. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Aitken A: 14-3-3 proteins on the MAP.
Trends Biochem Sci. 20:95–97. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Aitken A: 14-3-3 proteins: A historic
overview. Semin Cancer Biol. 16:162–172. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Muslin AJ, Tanner JW, Allen PM and Shaw
AS: Interaction of 14-3-3 with signaling proteins is mediated by
the recognition of phosphoserine. Cell. 84:889–897. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
van Hemert MJ, Steensma HY and van Heusden
GP: 14-3-3 proteins: key regulators of cell division, signalling
and apoptosis. Bioessays. 23:936–946. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tzivion G, Gupta VS, Kaplun L and Balan V:
14-3-3 proteins as potential oncogenes. Semin Cancer Biol.
16:203–213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhao J, Meyerkord CL, Du Y, Khuri FR and
Fu H: 14-3-3 proteins as potential therapeutic targets. Semin Cell
Dev Biol. 22:705–712. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Neal CL and Yu D: 14-3-3ζ as a prognostic
marker and therapeutic target for cancer. Expert Opin Ther Targets.
14:1343–1354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lu J, Guo H, Treekitkarnmongkol W, Li P,
Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, et al: 14-3-3zeta
Cooperates with ErbB2 to promote ductal carcinoma in situ
progression to invasive breast cancer by inducing
epithelial-mesenchymal transition. Cancer cell. 16:195–207. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Matta A, DeSouza LV, Shukla NK, Gupta SD,
Ralhan R and Siu KW: Prognostic significance of head-and-neck
cancer biomarkers previously discovered and identified using
iTRAQ-labeling and multidimensional liquid chromatography-tandem
mass spectrometry. J Proteome Res. 7:2078–2087. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Fan T, Li R, Todd NW, Qiu Q, Fang HB, Wang
H, Shen J, Zhao RY, Caraway NP, Katz RL, et al: Up-regulation of
14-3-3zeta in lung cancer and its implication as prognostic and
therapeutic target. Cancer Res. 67:7901–7906. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Muslin AJ and Xing H: 14-3-3 proteins:
Regulation of subcellular localization by molecular interference.
Cell Signal. 12:703–709. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Tzivion G and Avruch J: 14-3-3 proteins:
Active cofactors in cellular regulation by serine/threonine
phosphorylation. J Biol Chem. 277:3061–3064. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Benzinger A, Muster N, Koch HB, Yates JR
III and Hermeking H: Targeted proteomic analysis of 14-3-3 sigma, a
p53 effector commonly silenced in cancer. Mol Cell Proteomics.
4:785–795. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Jin J, Smith FD, Stark C, Wells CD,
Fawcett JP, Kulkarni S, Metalnikov P, O'Donnell P, Taylor P, Taylor
L, et al: Proteomic, functional, and domain-based analysis of in
vivo 14-3-3 binding proteins involved in cytoskeletal regulation
and cellular organization. Curr Biol. 14:1436–1450. 2004.
View Article : Google Scholar : PubMed/NCBI
|
